SIGA Technologies  

Company News

Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
PharmAthene (December 24, 2015)
SIGA Announces That Delaware Supreme Court Affirms Court of Chancery Opinion
SIGA Technologies (December 23, 2015)
SIGA Files Consensual Plan of Reorganization
SIGA Technologies (December 15, 2015)
PharmAthene Reports that SIGA has Filed its Reorganization Plan to Exit from Bankruptcy
PharmAthene (December 15, 2015)
PharmAthene Announces Conclusion of Oral Arguments In Its Litigation Against SIGA
PharmAthene (October 07, 2015)
Weekly Market Movers (to 15 Aug 2014) (August 18, 2014)
Daily Market Movers (11 Aug 2014) (August 12, 2014)

Displaying 10 out of a possible 235 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile SIGA Technologies (SIGAQ) is a New York based pharmaceutical company focused on development of therapeutic solutions for some of the most lethal disease causing pathogens including Ebola & other dangerous viruses.

17 SEP 2014: Received Bankruptcy Court approval of "first-day" motions.

16 SEP 2014: Company filed a voluntary petition for relief under Chapter 11 of the US Bankruptcy Code in the US Bankruptcy Court.
Listed or Private Company Listed
Company Classification Biotechnology
Country USA
Company Website Website
Technology Platform Profile
Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
11/08/2014 10 Aug: Company announces that the Delaware Court of Chancery issued a memorandum opinion on 8 Aug ordering SIGA to pay PharmAthene damages for the value of its lost profits from SIGA's smallpox antiviral, tecovirimat. 90 -38.7% -57

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
SIGA Technologies 1 22


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now